The effect of Daclizumab in a high-risk renal transplant population

Clinical Transplantation

Volumn 14, Issue 5, 2000, Pages 509-513

  Meier Kriesche, Herwig Ulf ^a   Kaza, Harsha ^b   Palekar, Sadanand S ^c   Friedman, Gary S ^b   Mulgaonkar, Shamkant P ^b   Ojo, Akinlolu O ^a   Kaplan, Bruce ^a,d  

^a UNIVERSITY OF MICHIGAN   (United States)

^b SAINT BARNABAS MEDICAL CENTER   (United States)

^c NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

African; American; Daclizumab; High risk; Hispanic; Immunosuppression; Induction; Kidney transplantation

Indexed keywords

ACICLOVIR; AZATHIOPRINE; CALCINEURIN; COTRIMOXAZOLE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ADULT; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; ETHNIC GROUP; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; INCIDENCE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MULTIVARIATE ANALYSIS; NEGRO; PRIORITY JOURNAL; RACE DIFFERENCE; RECIPIENT; RISK ASSESSMENT; UNITED STATES;

ADULT; AFRICAN AMERICANS; ANTIBODIES, MONOCLONAL; CASE-CONTROL STUDIES; FEMALE; GRAFT REJECTION; HISPANIC AMERICANS; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; PROSPECTIVE STUDIES;

EID: 0033814749     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0012.2000.140511.x     Document Type: Article

References (16)

1. Survival of patients undergoing renal replacement therapy in one center with special emphasis on racial differences
2. The effect of race and ethnicity on kidney allograft outcome
3. Late acute rejection is more prevalent among African-American renal allograft recipients and is frequently associated with allograft loss
4. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation
5. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: A phase II trial
6. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: A report of the United States Multicenter FK506 kidney transplant group
7. Immunosuppressive therapy in high-risk transplant patients: Dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients
8. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine
9. Effect of race and immunosuppression in renal transplantation: Three-year survival results from a US multicenter, randomized trial
10. Mycophenolate mofetil reduces the risk of acute rejection less in African-American than in Caucasian kidney recipients
11. Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era
12. Improving renal transplant outcomes in African Americans with OKT3 induction therapy
13. The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data
14. One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 kidney transplant group
15. A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation
16. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation